RxDoctor Payments Data

Paul Wang, MD

Clinical Cardiac Electrophysiology · Stanford, CANPI 1245342708

Payments from drug & device makers

$1,645in general payments, 2019–2025

Across 31 payments — averaging $53.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$312
  • Astrazeneca UK Limited$135
  • Amarin Pharma, Inc.$100
  • Bardy Diagnostics, Inc.$33
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$29
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$30619%
  • Food & beverage$1,34081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)19$1,022
Abbott6$312
Astrazeneca UK Limited1$135
Amarin Pharma, Inc.1$100
Bardy Diagnostics, Inc.1$33
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$29
Cardiva Medical, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,645 in reported general payments places this provider in the 5th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$137,756
Medicare patients
511
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$377,986
XareltoRivaroxaban71$91,468
MultaqDronedarone Hcl44$86,249
Enoxaparin Sodium85$5,033
Flecainide Acetate77$5,022
Dofetilide25$3,205
Amiodarone Hcl74$2,047
Metoprolol Succinate93$1,878
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,549
SotalolSotalol Hcl27$894
Sucralfate29$892
Digoxin16$608
Propafenone Hcl18$607
Pantoprazole Sodium39$296
Metoprolol Tartrate31$172

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →